On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $52.8 which represents a decrease of $-0.59 or -1.11% from the prior close of $53.39. The stock opened at $53.39 and touched a ...

An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung ...

Prenatal gene therapy via mRNA LNPs fixes faulty genes in fetal brain cells in animal model of neurodevelopmental syndrome.

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna shares rebound after six days of losses. Analysts mixed on stock with Strong Sell rating but potential for future growth.

A single COVID-19 mRNA vaccine dose provided similar protection to that conferred by a 2-dose series among immunocompetent patients aged 5 years and older.

Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the presentation of preclinical data that demonstrate a mechanism of uptake and ...

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

Montréal and UK-based startup Epitopea has raised $31 million USD ($43 million CAD) in what it called pre-Series A funding ...

According to an infectious disease expert, Hong Kong’s flu season is expected to start in December; it is likely to have two ...

On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.

Katalin Karikó, a Nobel Prize laureate, Penn professor, and renowned mRNA researcher from Abington, has been inducted into ...